MEIP / Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This mi more_horizontal

MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2023 Earnings Call Transcript September 26, 2023 5:00 PM ET Company Participants David Walsey - SVP, Corporate Affa more_horizontal

MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to los more_horizontal

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers more_horizontal

MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President more_horizontal

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold more_horizontal

The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 more_horizontal

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent more_horizontal